Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Part of paid clinical trials in San Francisco, California.

Sponsor
CellCentric Ltd.
Study ID
NCT07096778
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Multiple Myeloma Refractory
  • Multiple Myeloma in Relapse

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Inobrodib — DRUG
    20 mg orally twice daily (b.i.d.) 4 days on / 3 days off for each 28-day cycle.
  • Pomalidomide — DRUG
    4 mg orally once daily on Day 1 to 21 of each 28-day cycle
  • Dexamethasone — DRUG
    40 mg orally once daily on Days 1, 8, 15 and 22 for each 28-day cycle

Study Details

The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.

Key Dates

Start date
Jan 22, 2026
Status verified
May 2026
Primary completion
Dec 1, 2029
Completion
Dec 1, 2029

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Inobrodib in combination with pomalidomide and dexamethasone

Primary Outcome Measure

Objective Response Rate, defined as the percentage of patients with a confirmed partial response (PR) or better, based on IMWG criteria and assessed by Independent Review Committee (IRC) [ Time Frame: Assessed from enrollment to date of progressive disease or death from any cause, until the end of study (up to 48 months) ]

Central Contacts

Locations (12)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143-
H Lee Moffitt Cancer Center & Research InstituteTampaFlorida33612-
Winship Cancer InstituteAtlantaGeorgia30322-
American Oncology Partners, PABethesdaMaryland20817-
Washington University School of MedicineSt LouisMissouri63110-
University of Nebraska Medical CenterOmahaNebraska68198-
Rutgers Cancer Institute of New JerseyNew BrunswickNew Jersey08901-
Levine Cancer InstituteCharlotteNorth Carolina28204-
Wake Forest University Health SciencesWinston-SalemNorth Carolina27157-
Cleveland ClinicClevelandOhio44195-
University of Pennsylvania, Abramson Cancer CenterPhiladelphiaPennsylvania19104-
Fred Hutchinson Cancer CenterSeattleWashington98109-

Find similar trials in San Francisco, CA

By research site
University of California, San Francisco· San Francisco, CAH Lee Moffitt Cancer Center & Research Institute· Tampa, FLWinship Cancer Institute· Atlanta, GAAmerican Oncology Partners, PA· Bethesda, MDWashington University School of Medicine· St Louis, MOUniversity of Nebraska Medical Center· Omaha, NE

Related Studies